These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34677610)

  • 1. C3 glomerulopathy associated with monoclonal gammopathy: impact of chronic histologic lesions and beneficial effects of clone-targeted therapies.
    Caravaca-Fontán F; Lucientes L; Serra N; Cavero T; Rodado R; Ramos N; Gonzalez F; Shabaka A; Cabello V; Huerta A; Pampa-Saico S; Gutiérrez E; Quintana LF; López-Rubio ME; Draibe J; Alonso Titos J; Fernández-Juárez G; Goicoechea de Jorge E; Praga M
    Nephrol Dial Transplant; 2022 Oct; 37(11):2128-2137. PubMed ID: 34677610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C3 glomerulopathy associated with monoclonal Ig is a distinct subtype.
    Ravindran A; Fervenza FC; Smith RJH; Sethi S
    Kidney Int; 2018 Jul; 94(1):178-186. PubMed ID: 29729982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy.
    Chauvet S; Roumenina LT; Aucouturier P; Marinozzi MC; Dragon-Durey MA; Karras A; Delmas Y; Le Quintrec M; Guerrot D; Jourde-Chiche N; Ribes D; Ronco P; Bridoux F; Fremeaux-Bacchi V
    Front Immunol; 2018; 9():2260. PubMed ID: 30333829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy.
    Chauvet S; Frémeaux-Bacchi V; Petitprez F; Karras A; Daniel L; Burtey S; Choukroun G; Delmas Y; Guerrot D; François A; Le Quintrec M; Javaugue V; Ribes D; Vrigneaud L; Arnulf B; Goujon JM; Ronco P; Touchard G; Bridoux F
    Blood; 2017 Mar; 129(11):1437-1447. PubMed ID: 28069603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of a Histologic Scoring Index for C3 Glomerulopathy.
    Caravaca-Fontán F; Trujillo H; Alonso M; Díaz-Encarnación M; Cabello V; Ariceta G; Quintana LF; Marco H; Barros X; Ramos N; Rodríguez-Mendiola N; Cruz S; Fernández-Juárez G; Rodríguez E; de la Cerda F; Pérez de José A; López I; Fernández L; Pérez Gómez V; Ávila A; Bravo L; Lumbreras J; Allende N; Sanchez de la Nieta MD; Olea T; Melgosa M; Huerta A; Miquel R; Mon C; Fraga G; de Lorenzo A; Draibe J; González F; Shabaka A; Illescas ML; Calvo C; Oviedo V; Da Silva I; Goicoechea de Jorge E; Caravaca F; Praga M;
    Am J Kidney Dis; 2021 May; 77(5):684-695.e1. PubMed ID: 33359150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal Significance (MGRS)-Associated Lesions: A Case Series.
    Heybeli C; Alexander MP; Bentall AJ; Amer H; Buadi FK; Dean PG; Dingli D; Dispenzieri A; El Ters M; Gertz MA; Issa NS; Kapoor P; Kourelis T; Kukla A; Kumar S; Lacy MQ; Lorenz EC; Muchtar E; Murray DL; Nasr SH; Prieto M; Rajkumar SV; Schinstock CA; Stegall MD; Warsame R; Leung N
    Am J Kidney Dis; 2022 Feb; 79(2):202-216. PubMed ID: 34175375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 78-Year-Old Man with Chronic Kidney Disease and Monoclonal Gammopathy Who Developed Post-Transplant C3 Glomerulopathy - Recurrence or De Novo? A Case Report and Literature Review.
    Ruiz-Fuentes MC; Caba-Molina M; Polo-Moyano A; Palomares-Bayo M; Galindo-Sacristan P; De Gracia-Guindo C
    Am J Case Rep; 2023 Jun; 24():e939726. PubMed ID: 37329130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update to the pathogenesis for monoclonal gammopathy of renal significance.
    Zuo C; Zhu Y; Xu G
    Crit Rev Oncol Hematol; 2020 May; 149():102926. PubMed ID: 32199132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic.
    Ravindran A; Fervenza FC; Smith RJH; De Vriese AS; Sethi S
    Mayo Clin Proc; 2018 Aug; 93(8):991-1008. PubMed ID: 30077216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.
    Iatropoulos P; Noris M; Mele C; Piras R; Valoti E; Bresin E; Curreri M; Mondo E; Zito A; Gamba S; Bettoni S; Murer L; Fremeaux-Bacchi V; Vivarelli M; Emma F; Daina E; Remuzzi G
    Mol Immunol; 2016 Mar; 71():131-142. PubMed ID: 26895476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort.
    Michels MAHM; Wijnsma KL; Kurvers RAJ; Westra D; Schreuder MF; van Wijk JAE; Bouts AHM; Gracchi V; Engels FAPT; Keijzer-Veen MG; Dorresteijn EM; Volokhina EB; van den Heuvel LPWJ; van de Kar NCAJ
    Pediatr Nephrol; 2022 Mar; 37(3):601-612. PubMed ID: 34476601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.
    Holle J; Berenberg-Goßler L; Wu K; Beringer O; Kropp F; Müller D; Thumfart J
    Pediatr Nephrol; 2018 Dec; 33(12):2289-2298. PubMed ID: 30238151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three cases of monoclonal gammopathy of renal significance after kidney transplantation. De novo C3 glomerulopathy.
    Serra N; Facundo C; Canal C; Arce Y; Ayasreh N; Vila A; Bardají B; Silva I; López V; Benito S; Ballarín J; Guirado L
    Nefrologia (Engl Ed); 2019; 39(2):198-201. PubMed ID: 29914760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal immunoglobulin mediates complement activation in monoclonal gammopathy associated-C3 glomerulonephritis.
    Li LL; Li ZY; Wang SX; Yu XJ; Tan Y; Wang Y; Yu F; Zhao MH
    BMC Nephrol; 2019 Dec; 20(1):459. PubMed ID: 31823738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of C3 glomerulopathy patients: largest single-centre experience from South Asia.
    Kumar A; Nada R; Ramachandran R; Rawat A; Tiewsoh K; Das R; Rayat CS; Gupta KL; Vasishta RK
    J Nephrol; 2020 Jun; 33(3):539-550. PubMed ID: 31820418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C3 nephritic factor associated with C3 glomerulopathy in children.
    Nicolas C; Vuiblet V; Baudouin V; Macher MA; Vrillon I; Biebuyck-Gouge N; Dehennault M; Gié S; Morin D; Nivet H; Nobili F; Ulinski T; Ranchin B; Marinozzi MC; Ngo S; Frémeaux-Bacchi V; Pietrement C
    Pediatr Nephrol; 2014 Jan; 29(1):85-94. PubMed ID: 24068526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update to the pathogenesis for monoclonal gammopathy of renal significance.
    Zuo C; Zhu Y; Xu G
    Ann Hematol; 2020 Apr; 99(4):703-714. PubMed ID: 32103323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.
    Michels MAHM; van de Kar NCAJ; van Kraaij SAW; Sarlea SA; Gracchi V; Engels FAPT; Dorresteijn EM; van der Deure J; Duineveld C; Wetzels JFM; van den Heuvel LPWJ; Volokhina EB
    Front Immunol; 2021; 12():715704. PubMed ID: 34456924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan.
    Podos SD; Trachtman H; Appel GB; Bomback AS; Dixon BP; Wetzels JFM; Cook HT; Parikh SV; Pickering MC; Tumlin J; Langman CB; Lightstone L; Sperati CJ; Daina E; Bouman KP; Rice K; Thanassi JA; Huang M; Nester C; Remuzzi G
    Am J Nephrol; 2022; 53(10):675-686. PubMed ID: 36404708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining the complement biomarker profile of C3 glomerulopathy.
    Zhang Y; Nester CM; Martin B; Skjoedt MO; Meyer NC; Shao D; Borsa N; Palarasah Y; Smith RJ
    Clin J Am Soc Nephrol; 2014 Nov; 9(11):1876-82. PubMed ID: 25341722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.